Clearbridge Investments LLC Sells 517,449 Shares of Icon Plc $ICLR

Clearbridge Investments LLC cut its position in Icon Plc (NASDAQ:ICLR) by 45.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 616,991 shares of the medical research company’s stock after selling 517,449 shares during the quarter. Clearbridge Investments LLC owned about 0.76% of Icon worth $112,428,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. WINTON GROUP Ltd bought a new stake in shares of Icon during the 2nd quarter valued at $254,000. Daiwa Securities Group Inc. raised its stake in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after purchasing an additional 4,546 shares during the period. Frontier Capital Management Co. LLC raised its stake in shares of Icon by 97.6% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp bought a new stake in shares of Icon during the 2nd quarter valued at $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 289 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Icon Price Performance

Icon stock opened at $149.45 on Monday. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The business has a 50-day simple moving average of $117.51 and a 200 day simple moving average of $140.74. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. The stock has a market cap of $11.44 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 11.81 and a beta of 1.26.

Icon (NASDAQ:ICLR) last posted its earnings results on Wednesday, May 27th. The medical research company reported $2.21 EPS for the quarter. Icon had a return on equity of 9.50% and a net margin of 5.98%.The business had revenue of $2.11 billion during the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, research analysts forecast that Icon Plc will post 9.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ICLR. JPMorgan Chase & Co. boosted their price objective on Icon from $120.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, May 29th. Truist Financial boosted their price objective on Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research note on Friday, May 29th. Piper Sandler lowered Icon to a “neutral” rating in a research note on Thursday, May 28th. Royal Bank Of Canada boosted their price objective on Icon from $123.00 to $126.00 and gave the company a “sector perform” rating in a research note on Friday, May 29th. Finally, DA Davidson set a $164.00 target price on Icon in a research report on Monday, June 1st. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $156.44.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.